NCT05444322 is a EARLY_PHASE1 clinical trial of RD14-01 cell infusion in Mantle Cell Lymphoma, sponsored by He Huang.

Who is sponsoring NCT05444322?

NCT05444322 is sponsored by He Huang.

What drugs are being tested in NCT05444322?

Interventions in NCT05444322: RD14-01 cell infusion.

What condition does NCT05444322 study?

NCT05444322 studies Mantle Cell Lymphoma, Diffuse Large B-cell Lymphoma, Follicular Lymphoma.

Is NCT05444322 still recruiting?

NCT05444322 is currently status unknown. Last updated 11 July 2022.

Last reviewed 2022-07-11 · How we verify

NCT05444322

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of RD14-01 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

Status unknown EARLY_PHASE1 Last updated 11 July 2022

What this trial tests

EARLY_PHASE1 trial testing RD14-01 cell infusion in Mantle Cell Lymphoma in 18 participants. Status unknown.

Timeline

5 July 2022

Primary endpoint
10 July 2024

10 July 2025

Quick facts

Lead sponsor	He Huang
Phase	EARLY_PHASE1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	18
Start date	5 July 2022
Primary completion	10 July 2024
Estimated completion	10 July 2025
Sites	1 location across China

Drugs / interventions tested

RD14-01 cell infusion — full drug profile →

Conditions studied

Mantle Cell Lymphoma — all drugs for Mantle Cell Lymphoma →
Diffuse Large B-cell Lymphoma — all drugs for Diffuse Large B-cell Lymphoma →
Follicular Lymphoma — all drugs for Follicular Lymphoma →

Sponsor

He Huang — full company profile →

Who can join

Adults 18 to 75, any sex, with Mantle Cell Lymphoma or Diffuse Large B-cell Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is designed to explore the safety and tolerability of RD14-01 for patients with relapsed and/or refractory B-cell non-Hodgkin lymphoma. And to evaluate the efficacy and pharmacokinetics of RD14-01 in patients.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Beyond Bruton's tyrosine kinase inhibitors in mantle cell lymphoma: bispecific antibodies, antibody-drug conjugates, CAR T-cells, and novel agents.
Jain N, Mamgain M, Chowdhury SM, Jindal U, et al · · 2023 · cited 19× · PMID 37626420 · DOI 10.1186/s13045-023-01496-4
Empowering macrophages: the cancer fighters within the tumour microenvironment in mantle cell lymphoma.
Nylund P, Nikkarinen A, Ek S, Glimelius I. · · 2024 · cited 5× · PMID 38566987 · DOI 10.3389/fimmu.2024.1373269
Generating advanced CAR-based therapy for hematological malignancies in clinical practice: targets to cell sources to combinational strategies.
Zhou S, Yang Y, Jing Y, Zhu X. · · 2024 · cited 3× · PMID 39372412 · DOI 10.3389/fimmu.2024.1435635
Next-Generation Therapies in Mantle Cell Lymphoma (MCL): The Evolving Landscape in Treatment of Relapse/Refractory After CAR-T Cells.
Boccellato E, Comba L, Tavarozzi R, Castellino C, et al · · 2025 · cited 2× · PMID 40647536 · DOI 10.3390/cancers17132239

Verify or expand the search:

Other recruiting trials for Mantle Cell Lymphoma

Currently open trials in the same condition.

NCT07377578 — A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cel · Phase 3 · recruiting
NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr · Phase 2 · recruiting
NCT06839053 — Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic L · Phase 2 · recruiting
NCT06357676 — Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial · Phase 1, PHASE2 · recruiting
NCT06854003 — BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Fo · Phase 2 · recruiting

Other He Huang trials

Trials by the same sponsor.

NCT06887985 — JY231(JY231) Injection for the Treatment of Refractory Autoimmune Diseases (ADs) · NA · not yet recruiting
NCT06902025 — JY231(JY231) Injection for the Treatment of Relapsed or Refractory B-Cell Leukemia · NA · not yet recruiting
NCT06785519 — CD19/BCMA CAR-T Cell Therapy for Refractory/Relapsed Lupus Nephritis · EARLY_PHASE1 · recruiting
NCT06709131 — A Clinical Study to Explore the Safety and Efficacy of CT0991 in Relapsed/Refractory Acute Myeloid Leukemia · Phase 1 · suspended
NCT06571825 — RIC Allo-HSCT vs. Venetoclax-Based Consolidation in Elderly AML Patients After First CR · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05444322 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by He Huang
Last refreshed: 11 July 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05444322.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing